Navigation Links
£6.5M in funding to help manufacture the drugs of the future
Date:2/5/2013

y to manufacture the biopharmaceuticals of the future in an efficient and sustainable way. It is a timely prelude to our continuing support for bioprocessing research under our Industrial Biotechnology and Bioenergy Strategy."

Mr Atti Emecz, EPSRC Director Strategy and Business Relationships, said: "This investment demonstrates the value of the BRIC approach. It draws together bioscience, chemistry and engineering to tackle multidisciplinary challenges and promote internationally excellent research. It also develops the valuable partnerships with industry needed to deliver impact."

Ten BRIC Studentships have also been funded by BBSRC to help develop the bioprocessing researchers of the future. This brings the total number of BRIC students to 28, each with a collaborating BRIC member company.

BRIC Studentships are collaborative training grants, which follow the Industrial CASE model, giving these top bioprocessing PhD students the chance to experience first-rate research at both an academic institution and within an industrial setting.

The ten studentships will start in the 2013/14 academic year, and last for up to four years, based at five UK universities in partnership with six collaborating companies/organisations.

Students will spend a minimum of three months in a placement with the industrial partner learning skills that they will not necessarily acquire during a standard doctoral programme.

As well as providing high-quality training the scheme develops networking links between students, academia and industry.

The programme complements the EPSRC-funded Doctoral Training Centres at Newcastle and UCL that are relevant to the bioprocessing sector and other EPSRC studentship investments, by supporting training with a biosciences focus.

The funded BRIC research projects are:

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Rajendra Singh Thursday as a "Champion of Change" ... deployment in the residential, commercial and industrial sectors. ... Electrical and Computer Engineering and director of Clemson,s ... hero leading the charge across the country to ... and driving policy changes at the local level ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
(Date:4/17/2014)... University researchers have detected new early-warning signs of the ... could have far-reaching implications for the diagnosis and treatment ... 25 million Americans. , "We had not expected to ... early stages," said Ann Elsner, professor and associate dean ... of the study. "We set out to study the ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Nature Genetics, is based on data from more than ... but also discovered ten new genes. Altogether they explain ... The analysis produced some biologically insightful findings. Several ... let-7, which affects the regulation of other genes. This ...
... University of Leicester engineer has won a share of ... cancer. In an unusual move, Dr. Declan Bates, ... the University of Leicester, is co-recipient of 1,068,000 in ... the Engineering and Physical Sciences Research Council (EPSRC) and ...
... to determine if global warming threatens the polar bear population ... listing the polar bear as an endangered species, according to ... journal of the Institute for Operations Research and the Management ... ordered the Interior Department to decide by May 15 whether ...
Cached Biology News:How body size is regulated 2Engineer to spearhead research into cell metabolism and medical injuries 2Federal polar bear research critically flawed, says study in INFORMS journal 2
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... MA (PRWEB) January 14, 2014 iLab Solutions, ... Detwiler as the new Director of Product Strategy. In this ... well as iLab sub-teams to guide in the development of ... iLab provides the maximum possible benefit to the scientific community ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) announced today financial ... 30, 2008., Third Quarter and Nine Months Financial ... months ended Sept. 30, 2008, was,$3.8 million and $12.2 ... in 2007. Revenue in the third quarter and nine,months ...
... and Two Divestitures of Non-Core Product Lines -, ... Inc. (Nasdaq: CALP ) today reported third ... two product line divestitures: the,sale of its AutoTrace(R) ... the sale of its Pharmaceutical Development and Quality ...
... be Webcast -, MONTVALE, N.J. ,Nov. 10 ... Noah Berkowitz, M.D.,Ph.D., President and Chief Executive Officer of ... on Tuesday, November 11, at 2:25,p.m. Eastern Time. The ... the New,York Palace Hotel in New York City., ...
Cached Biology Technology:Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 2Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 3Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 4Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 5Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 6Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 7Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 8Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 9Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 10Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs 11Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference 2
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Biology Products: